Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.

By R. Fleischmann, J. Kremer, J. Cush, H. Schulze-Koops, C. Connell, J. Bradley, D. Gruben, G. Wallenstein, S. Zwillich, K. Kanik. New England Journal of Medicine, 2012

920 citations recorded by the source corpus.

Subfields: Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/bd1b82eccaeaacf348e9bf6800c9368dd73196be

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. I. McInnes

In Rheumatology

1. I. McInnes
2. J. O’Shea
3. S. Gaffen

Citations in the corpus

• Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. (2012, neutral): “(%) 12 (25) 2 (6) 6 (18) 6 (18) 10 (20) 0.”
• The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention (2015, background): “Cardiovascular events in patients on tofacitinib have been reported (60, 73, 74).”